Our study revealed a negative correlation between FANCD2 expression and the IC50 value of sorafenib in Hepatitis B-related HCC, indicating that patients with higher FANCD2 expression are more likely to have a better therapeutic response to sorafenib. This evidence concerns the gene FANCD2 and hepatitis B virus infection.